

Amendments to the claims:

Please cancel claims 6 and 16 without prejudice to their renewal in a related patent application.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of treating a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering a BMP antagonist to a subject suffering from a BMP-related disorder or condition, wherein the BMP-related disorder or condition is treated, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2) or hNOGΔB2 (SEQ ID NO:10), ~~a noggin variant, or a fragment thereof capable of acting as a BMP antagonist.~~

2. (original) The method of claim 1, wherein the BMP-related disorder or condition is heterotopic cranial synostosis, fibrodysplasia ossificans progressiva (FOP), or sclerostosis.

3-9. (canceled)

10. (currently amended) A method of blocking biological activity of a bone morphogenetic protein (BMP) in a subject, comprising administering an agent capable of blocking BMP biological activity, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2) or hNOGΔB2 (SEQ ID NO:10), ~~a noggin variant, or a fragment thereof capable of acting as a BMP antagonist.~~

11. (currently amended) The method of claim 10, wherein the BMP-related disorder or condition is cariessynostosis heterotropic cranial synostosis or fibrodysplasia ossificans progressiva (FOP).

12-19. (canceled)

USSN 10/735,345
Office action dated 28 November 2006
Response dated 23 February 2007

20. (currently amended) A method of inhibiting the progress of a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering ~~the pharmaceutical composition of claim 19~~ human noggin (hNOG) (SEQ ID NO:2) or hNOGΔB2 (SEQ ID NO:10) to a subject suffering from a BMP-related disorder or condition, wherein the BMP-related disorder or condition is treated.